RT Journal Article
SR Electronic
T1 Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
JF RMD Open
JO RMD Open
FD EULAR
SP e002508
DO 10.1136/rmdopen-2022-002508
VO 8
IS 2
A1 Su-Ann Yeoh
A1 Milena Gianfrancesco
A1 Saskia Lawson-Tovey
A1 Kimme L Hyrich
A1 Anja Strangfeld
A1 Laure Gossec
A1 Loreto Carmona
A1 Elsa F Mateus
A1 Martin Schäfer
A1 Christophe Richez
A1 Eric Hachulla
A1 Marie Holmqvist
A1 Carlo Alberto Scirè
A1 Hanns-Martin Lorenz
A1 Reinhard E Voll
A1 Rebecca Hasseli
A1 Arundathi Jayatilleke
A1 Tiffany Y-T Hsu
A1 Kristin M D’Silva
A1 Victor R Pimentel-Quiroz
A1 Monica Vasquez del Mercado
A1 Samuel Katsuyuki Shinjo
A1 Edgard Torres dos Reis Neto
A1 Laurindo Ferreira da Rocha Junior
A1 Ana Carolina de Oliveira e Silva Montandon
A1 Guillermo J Pons-Estel
A1 Sofía Ornella
A1 Maria Eugenia D'Angelo Exeni
A1 Edson Velozo
A1 Paula Jordan
A1 Emily Sirotich
A1 Jonathan S Hausmann
A1 Jean W Liew
A1 Lindsay Jacobsohn
A1 Monique Gore-Massy
A1 Paul Sufka
A1 Rebecca Grainger
A1 Suleman Bhana
A1 Zachary Wallace
A1 Philip C Robinson
A1 Jinoos Yazdany
A1 Pedro M Machado
A1 ,
YR 2022
UL http://rmdopen.bmj.com/content/8/2/e002508.abstract
AB Objectives To investigate factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy (IIM).Methods Demographic data, clinical characteristics and COVID-19 outcome severity of adults with IIM were obtained from the COVID-19 Global Rheumatology Alliance physician-reported registry. A 3-point ordinal COVID-19 severity scale was defined: (1) no hospitalisation, (2) hospitalisation (and no death) and (3) death. ORs were estimated using multivariable ordinal logistic regression. Sensitivity analyses were performed using a 4-point ordinal scale: (1) no hospitalisation, (2) hospitalisation with no oxygen (and no death), (3) hospitalisation with oxygen/ventilation (and no death) and 4) death.Results Of 348 patients, 48% were not hospitalised, 39% were hospitalised (and did not die) and 13% died. Older age (OR=1.59/decade, 95% CI 1.31 to 1.91), high disease activity (OR=3.50, 95% CI 1.25 to 9.83; vs remission), ≥2 comorbidities (OR=2.63, 95% CI 1.39 to 4.98; vs none), prednisolone-equivalent dose >7.5 mg/day (OR=2.40, 95% CI 1.09 to 5.28; vs no intake) and exposure to rituximab (OR=2.71, 95% CI 1.28 to 5.72; vs conventional synthetic disease-modifying antirheumatic drugs only) were independently associated with severe COVID-19. In addition to these variables, in the sensitivity analyses, male sex (OR range: 1.65–1.83; vs female) was also significantly associated with severe outcomes, while COVID-19 diagnosis after 1 October 2020 (OR range: 0.51–0.59; vs on/before 15 June 2020) was significantly associated with less severe outcomes, but these associations were not significant in the main model (OR=1.57, 95% CI 0.95 to 2.59; and OR=0.61, 95% CI 0.37 to 1.00; respectively).Conclusions This is the first large registry data on outcomes of COVID-19 in people with IIM. Older age, male sex, higher comorbidity burden, high disease activity, prednisolone-equivalent dose >7.5 mg/day and rituximab exposure were associated with severe COVID-19. These findings will enable risk stratification and inform management decisions for patients with IIM.Data are available on reasonable request. Applications to access the data should be made to the COVID-19 Global Rheumatology Alliance Steering Committee.